Validation of the Italian version of the PSP Quality of Life questionnaire

Picillo, Marina; Cuoco, Sofia; Amboni, Marianna; Bonifacio, Francesco Paolo; Bruschi, Fabio; Carotenuto, Immacolata; Rosa, Anna De; Prete, Eleonora Del; Biasio, Francesca Di; Elifani, Francesca; Erro, Roberto; Fabbri, Margherita; Falla, Marika; Franco, Giulia; Frosini, Daniela; Galantucci, Sebastiano; Lazzeri, Giulia; Magistrelli, Luca; Malaguti, María Chiara; Milner, Anna Vera; Minafra, Brigida; Olivola, Enrica; Padovani, Alessandro; Rascunà, Cristina; Rizzetti, Maria Cristina; Schirinzi, Tommaso; Borroni, Barbara; Ceravolo, Roberto; Fonzo, Alessio Di; Marchese, Roberta; Mercuri, Nicola Biagio; Modugno, Nicola; Padovani, Alessandro; Santangelo, Gabriella; Stefani, Alessandro; Tessitore, Alessandro; Volontè, Maria Antonietta; Zangaglia, Roberta; Zappia, Mario; Zibetti, Maurizio; Barone, Paolo

doi:10.1007/s10072-019-04010-2

Cited by 10 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The novelty of the present study consists in the preliminary evaluation of the psychometric properties of the tool used to measure depression in PSP. Similarly, the PSP‐QoL underwent language validation in an independent set of Italian patients (Picillo Cuoco, Amboni, Bonifacio, Bruschi, et al., 2019 ). Indeed, such formal validation of all the scales used represents a point of strength of the present work.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Psychometric properties of the Beck Depression Inventory‐II in progressive supranuclear palsy

et al. 2021

Self Cite

View full text Add to dashboard Cite

Objectives: Depression is one of the most common neuropsychiatric symptoms in progressive supranuclear palsy (PSP). Yet, few studies have examined the ability of available instruments to detect depressive symptoms in PSP. Aims of the present study were to (I) report psychometric properties of the Beck Depression Inventory Second Edition (BDI-II) in PSP, (II) establish the BDI-II cut-off indicating the presence of depression in PSP and (III) describe clinical correlates as well as correlation with quality of life of depressive symptoms in PSP. Design, setting and participants: : At the Center for Neurodegenerative Diseases of the University of Salerno, Italy, the BDI-II was validated in 62 PSP patients diagnosed according to the Movement Disorder Society criteria. Patients underwent a clinical interview, a motor evaluation, extensive cognitive and behavioral testing. Results:The mean BDI-II total score was 15.92 ± 10.31. The internal consistency was high (Cronbach's alpha = 0.868); corrected item-total correlation was >0.40 for the majority of items. The significant and moderate correlation of the BDI-II with other tools evaluating depressive symptoms indicated adequate convergent validity of the scale. The satisfactory cut-off to identify patients with clinically significant depression was >14.5. We also showed a correlation between higher scores on BDI-II and lower quality of life, irrespective of motor and cognitive burden. Conclusion:In conclusion, the BDI-II is a reliable and valid tool for the assessment of depression symptoms in PSP. Such data are useful to standardize studies of depression in PSP and to quantify the effectiveness of any interventions on this disabling symptom.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Furthermore, quality of life was evaluated with the Progressive Supranuclear Palsy Quality of Life Questionnaire (PSP‐QoL) (Picillo, Cuoco, Amboni, Bonifacio, Bruschi, et al., 2019 ) and apathy with Apathy Evaluation Scale (AES).…”

Section: Methodsmentioning

confidence: 99%

Psychometric properties of the Beck Depression Inventory‐II in progressive supranuclear palsy

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Multiple large European [4] [-] [6,11,12], North American [3] and Asian [7] studies of PSP cohorts have shown a mean time from symptom onset to diagnosis of approximately 3 years. The average time from assessment to diagnosis in our study of 7-8 years is therefore 4-5 years longer than expected symptom to diagnosis duration, and therefore suggests an early prediagnostic phase at the time of assessment.…”

Section: Discussionmentioning

confidence: 99%

“…Progressive Supranuclear Palsy (PSP) is a devastating and rapidly progressive disorder with a poor prognosis once diagnosed, compounded by a typical delay between symptom onset and diagnosis of approximately three years in Europe, North America and Asia [1][2][3][4][5][6][7]. In contrast to Parkinson's disease and genetic forms of dementia (e.g.…”

Section: Introductionmentioning

confidence: 99%

Prediagnostic Progressive Supranuclear Palsy – Insights from the UK Biobank

Street

Whiteside

Rittman

et al. 2022

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

Introduction: Prediagnostic features of Parkinson's Disease are well described but prediagnostic Progressive Supranuclear Palsy (PSP) is less understood. The diagnosis of PSP is delayed by an average of three years after symptom onset. Understanding the changes that occur in the prediagnostic period will aid earlier diagnosis, clarify the natural history, and may aid the design of early disease-modifying therapy trials. We set out to identify motor and cognitive markers of prediagnostic PSP, with Parkinson's disease as a comparator condition, in a large prospective cohort. Methods: Baseline UK Biobank data from 502,504 individuals were collected between 2006 and 2010. Subsequent PSP and Parkinson's disease cases were identified from primary and secondary care electronic health records' diagnostic coding data and death registry, with 5404 matched controls. Results: 176 PSP cases (time to diagnosis 7.8 ± 2.8 years) and 2526 Parkinson's disease cases (time to diagnosis 7.8 ± 2.9 years) were identified. At baseline, those later diagnosed with PSP had slower reaction times, weaker hand grip, lower fluid intelligence, prospective memory, self-rated health scores and digit recall than controls. Reaction times were correlated with time to diagnosis. The PSP group had higher mortality than both Parkinson's disease and control groups. Conclusions: Motor slowing, cognitive dysfunction, and postural instability are clinical diagnostic features of PSP that are typically symptomatic three years before diagnosis. Objective markers of these features were evident on average 7.8 years before diagnosis. Our findings suggest the existence of a long prediagnostic phase in PSP, with subtle changes in motor and cognitive function.

show abstract

“…half of the full range of the scale). More specifically, the following BFIs addressed to clinical populations reached a BFIQA score ≥25: ALS Depression Inventory [36], Apathy Evaluation Scale-Self Report version [44,51], Anosognosia Questionnaire Dementia [17], Bedford Alzheimer Nursing Severity Scale [4], Beaumont Behavioural Inventory [20], Beck Depression Inventory-II [11,64] Care-Related Quality of Life [63], Coop/Wonca [37], Disability Assessment Dementia Scale [12], Dimensional Apathy Scale [46,53,54], Dual-Task Impact in Daily-living Activities Questionnaire [38], Electronic format of Multiple Sclerosis Quality of Liufe-29 [48], Epilepsy-Quality of Life [40], Frontal Behavioural Inventory [2,29], Geriatric Handicap Scale [62], Hospital Anxiety and Depression Scale [31], Hamilton Depression Rating Scale [33,43,45], Medical Outcomes Study-Human Immunodeficiency Virus [59], Multiple Sclerosis Quality of Life-29 [47], Multiple Sclerosis Quality of Life-54 [56], Neuropsychiatric Invenotry-Nursing Home version [3], Non-Motor Symptoms Scale for Parkinson's disease [9], Non-Communicative Patient's Pain Assessment Instrument [15], Observer-Rated version of the Parkinson Anxiety Scale [53], Pain Assessment in Advanced Dementia [8,32], Progressive Supranuclear Palsy-Quality of Life [41], Quality of Life in Alzheimer's Disease [5], Quality of Life in the Dysarthric Speaker [39], Quality of Life after Brain Injury…”

Section: Overviewmentioning

confidence: 99%

Psychometrics, diagnostics and usability of Italian tools assessing behavioural and functional outcomes in neurological, geriatric and psychiatric disorders: a systematic review

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background Psychometric instruments assessing behavioural and functional outcomes (BFIs) in neurological, geriatric and psychiatric populations are relevant towards diagnostics, prognosis and intervention. However, BFIs often happen not to meet methodological-statistical standards, thus lowering their level of recommendation in clinical practice and research. This work thus aimed at (1) providing an up-to-date compendium on psychometrics, diagnostics and usability of available Italian BFIs and (2) delivering evidence-based information on their level of recommendation. Methods This review was pre-registered (PROSPERO ID: CRD42021295430) and performed according to PRISMA guidelines. Several psychometric, diagnostic and usability measures were addressed as outcomes. Quality assessment was performed via an ad hoc checklist, the Behavioural and Functional Instrument Quality Assessment. Results Out of an initial N = 830 reports, 108 studies were included (N = 102 BFIs). Target constructs included behavioural/psychiatric symptoms, quality of life and physical functioning. BFIs were either self- or caregiver-/clinician-report. Studies in clinical conditions (including neurological, psychiatric and geriatric ones) were the most represented. Validity was investigated for 85 and reliability for 80 BFIs, respectively. Criterion and factorial validity testing were infrequent, whereas content and ecological validity and parallel forms were almost never addressed. Item response theory analyses were seldom carried out. Diagnostics and norms lacked for about one-third of BFIs. Information on administration time, ease of use and ceiling/floor effects were often unreported. Discussion Several available BFIs for the Italian population do not meet adequate statistical-methodological standards, this prompting a greater care from researchers involved in their development.

show abstract

Validation of the Italian version of the PSP Quality of Life questionnaire

Cited by 10 publications

References 13 publications

Psychometric properties of the Beck Depression Inventory‐II in progressive supranuclear palsy

Psychometric properties of the Beck Depression Inventory‐II in progressive supranuclear palsy

Prediagnostic Progressive Supranuclear Palsy – Insights from the UK Biobank

Psychometrics, diagnostics and usability of Italian tools assessing behavioural and functional outcomes in neurological, geriatric and psychiatric disorders: a systematic review

Contact Info

Product

Resources

About